Please login to the form below

Not currently logged in
Email:
Password:

In the Wild

This page shows the latest In the Wild news and features for those working in and with pharma, biotech and healthcare.

Speedy approval for Pfizer's Onpattro rival

Speedy approval for Pfizer's Onpattro rival

Cardiomyopathy (CM) is the most serious of the symptoms seen in patients with hereditary or wild-type transthyretin-mediated amyloidosis (ATTR), a condition that means a protein known as transthyretin fails ... The FDA approval means these treatments

Latest news

  • FDA halts study of Teva and Regeneron's pain drug fasinumab FDA halts study of Teva and Regeneron's pain drug fasinumab

    However, the updated results revealed what might be a dose-dependent increase in the risk of arthropathy with the drug. ... view the candidates still in trials as wild cards, potentially offering big rewards but also a having a high risk of failure.

  • NICE backs BMS' Opdivo for melanoma NICE backs BMS' Opdivo for melanoma

    We welcome [the] decision from NICE, which is positive news for melanoma patients in the UK," said Johanna Mercier, general manager of BMS in the UK and Ireland. ... approval. The green light means that the cancer immunotherapy combination can be used in

  • New behavioural science comms consultancy launches New behavioural science comms consultancy launches

    In the Wild's managing director Andrew Martello said: “Our clients are innovators in the pharmaceutical industry who see the untapped potential of behavioural science. ... Brighton, UK-based consultancy In the Wild says it will focus on creating

  • Erbitux betters Avastin in bowel cancer subgroup Erbitux betters Avastin in bowel cancer subgroup

    However, new data presented at the Congress suggests that Merck's drug may be superior in the subset of patients with RAS wild-type mCRC – a form of mCRC associated with ... overall survival and may in part explain why we are seeing the overall

  • Information seen as main future health issue

    A forum headed by WPP has highlighted 'information proliferation' as the main issue in the future of healthcare in the EU. ... In all sessions, however, the most pressing matter in information proliferation was that it was 'in the wild'.

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics